For the quarter ending 2026-03-31, TYRA had $7,568K increase in cash & cash equivalents over the period. -$32,659K in free cash flow.
| Cash Flow | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| Net loss | -39,305 | -33,834 | -86,113 | - |
| Depreciation | 138 | 132 | 414 | - |
| Stock-based compensation | 7,847 | 7,627 | 20,379 | - |
| Accretion of marketable securities, net | -25 | -126 | -1,993 | - |
| Prepaid expenses and other assets | 2,438 | -404 | 5,484 | - |
| Accounts payable, accrued expenses and other liabilities | 1,195 | 2,156 | 1,213 | - |
| Right-of-use assets and lease liabilities, net | 17 | 17 | 66 | - |
| Net cash used in operating activities | -32,571 | -23,624 | -71,518 | - |
| Purchases of marketable securities | 162,206 | 9,106 | 92,148 | - |
| Maturities of marketable securities | 42,050 | 43,540 | 130,318 | - |
| Purchases of property and equipment | 88 | 57 | 84 | - |
| Net cash provided by (used in) investing activities | -120,244 | 34,377 | 38,086 | - |
| Proceeds from issuances of common stock under benefit plans | 12,530 | 4,683 | 3,417 | - |
| Proceeds from issuance of common stock and pre-funded warrants from private placement | - | 0 | 0 | - |
| Payments of issuance costs for common stock and pre-funded warrants from private placement | - | 0 | 0 | - |
| Proceeds from issuances of common stock under at-the-market offering program, net of 2.1 million of issuance costs | 147,853 | - | - | - |
| Net cash provided by financing activities | 160,383 | 4,683 | 3,417 | - |
| Restricted cash | - | - | - | 1,000 |
| Net cash increase (decrease) for the period | 7,568 | 15,436 | -30,015 | - |
| Cash and cash equivalents | - | - | - | 98,490 |
| Cash, cash equivalents and restricted cash at beginning of the period | 78,387 | 62,951 | 99,490 | - |
| Cash, cash equivalents and restricted cash at end of the period | 85,955 | 78,387 | 62,951 | 99,490 |
Tyra Biosciences, Inc. (TYRA)
Tyra Biosciences, Inc. (TYRA)